Cecilia Brown

DocwireNews

Persistent airflow limitation can occur in patients with mild asthma and is associated with eosinophilic inflammation and a higher risk of exacerbations, according to a post-hoc analysis of the ATLANTIS study.
Tessa Kole, MD, of the University Medical Center Groningen and the Groningen Research Institute for Asthma and COPD, and colleagues conducted the post-hoc analysis and published their findings in The Lancet Respiratory Medicine.
The study included adults up to 65 years old who were diagnosed with asthma at least 6 months before the study and who had available data on their post-bronchodilator forced expiratory volume in 1 second and forced vital capacity (n=760). The mean patient age was 44 years, and 58% of patients were women. Most patients were never smokers (76%), and 33% had persistent airflow limitation.
Persistent airflow limitation was detected in patients with severe asthma, but also was reported in 16% of patients receiving Global Initiative for Asthma (GINA) step 1 treatment and in 29% of patients receiving GINA step 2 treatment.
At a 1-year follow-up, persistent airflow limitation was independently associated with older age (46 years old in patients with persistent airflow limitation vs 43 years old in patients without persistent airflow limitation). It also was associated with a longer duration of asthma (24 years vs 12 years), being male (51% vs 38%), higher blood eosinophil counts, a higher frequency of small airway dysfunction, and more exacerbations.
“[Persistent airflow limitation] is not only present in severe disease, but also in a considerable proportion of patients with milder disease,” Dr. Kole and colleagues concluded. “In patients with mild asthma, [persistent airflow limitation] is associated with eosinophilic inflammation and a higher risk of exacerbations. Our findings are important because they suggest that increasing treatment intensity should be considered in patients with milder asthma and [persistent airflow limitation].”
Kole TM, Vanden Berghe E, Kraft M, et al. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study. Lancet Respir Med. 2022. doi:10.1016/S2213-2600(22)00185-0

Persistent airflow limitation can occur in patients with mild asthma and is associated with eosinophilic inflammation and a higher risk of exacerbations, according to a post-hoc analysis of the ATLANTIS study.Tessa Kole, MD, of the University Medical Center Groningen and the Groningen Research Institute for Asthma and COPD, and colleagues conducted the post-hoc analysis and published their findings in The Lancet Respiratory Medicine.The study included adults up to 65 years old who were diagnosed with asthma at least 6 months before the study and who had available data on their post-bronchodilator forced expiratory volume in 1 second and forced vital capacity (n=760). The mean patient age was 44 years, and 58% of patients were women. Most patients were never smokers (76%), and 33% had persistent airflow limitation.Persistent airflow limitation was detected in patients with severe asthma, but also was reported in 16% of patients receiving Global Initiative for Asthma (GINA) step 1 treatment and in 29% of patients receiving GINA step 2 treatment.At a 1-year follow-up, persistent airflow limitation was independently associated with older age (46 years old in patients with persistent airflow limitation vs 43 years old in patients without persistent airflow limitation). It also was associated with a longer duration of asthma (24 years vs 12 years), being male (51% vs 38%), higher blood eosinophil counts, a higher frequency of small airway dysfunction, and more exacerbations.“[Persistent airflow limitation] is not only present in severe disease, but also in a considerable proportion of patients with milder disease,” Dr. Kole and colleagues concluded. “In patients with mild asthma, [persistent airflow limitation] is associated with eosinophilic inflammation and a higher risk of exacerbations. Our findings are important because they suggest that increasing treatment intensity should be considered in patients with milder asthma and [persistent airflow limitation].”Kole TM, Vanden Berghe E, Kraft M, et al. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study. Lancet Respir Med. 2022. doi:10.1016/S2213-2600(22)00185-0

Michael Wheeler, PhD

Can Psychedelics Rewire Brain Circuits to Treat Mental Health Disorders?

Mental Health

Kelly McCann, MD, PhD

Treatment Sequencing Strategies in HR-Positive, HER2-Negative Breast Cancer

HR Breast Cancer

Treatment Sequencing Strategies in HER2-Positive Breast Cancer

HER2 Breast Cancer

Latest News

Persistent Airflow Limitation Increases Exacerbation Risk in Patients With Mild Asthma

Asthma

Persistent airflow limitation can occur in patients with mild asthma and is associated with eosinophilic inflammation and a higher risk of exacerbations, according to a ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe